MedTrace Logo

Alteration of Different Immune Parameters in Immune Thrombocytopenia （ITP） Patients Receiving Eltrombopag Treatment

NCT01864512 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2016-04-20

No results posted yet for this study

Summary

This project was undertaken by Qilu Hospital of Shandong University and other well-known hospitals in China. In order to report the alteration of Different Immune Parameters in ITP Patients Receiving Eltrombopag Treatment.

Conditions

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • Shandong University

    lead OTHER

Principal Investigators

  • Jun Peng, Doctor · Qilu Hospital, Shandong University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-03-31
Completion
2014-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01864512 on ClinicalTrials.gov